한글목차

전 세계 여성 고유 질환 치료제 시장 규모는 2024년 615억 달러에서 예측 기간 동안 CAGR 5.7%로 성장하여 2029년 말에는 812억 달러에 달할 것으로 예상됩니다.

북미 시장은 2024년 284억 달러에서 예측 기간 동안 5.6%의 CAGR로 성장하여 2029년 말에는 374억 달러에 달할 것으로 예상됩니다. 유럽 시장은 2024년 177억 달러에서 예측 기간 동안 CAGR 5.8%로 성장하여 2029년 말에는 235억 달러에 달할 것으로 예상됩니다.

세계의 여성 고유 질환 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 분석

제2장 시장 개요

• 개요
• 정의
• 유방암
• 폐경후 골다공증
• 폐경
• 자궁내막증
• 다낭성난소증후군(PCOS)
• 역사적 배경
• 노화와 여성 건강 장애

제3장 시장 역학

• 개요
• 시장 성장 촉진요인
• 고령 여성 인구 증가
• 인지도와 접근성 향상
• 시장 성장 억제요인
• 고액의 치료비
• 규제상 과제
• 시장 기회
• 맞춤형 의료의 진보
• 신흥 시장

제4장 신기술

• 개요
• 디지털 헬스 솔루션
• 첨단 불임 치료 기술
• 표적 생물학적 제제와 바이오시밀러
• 나노기술에 의한 약물전달
• 유전자 치료와 CRISPR

제5장 파이프라인 평가와 분석

• 개요
• 여성 고유 질환 치료제 : 주요 임상시험 진전
• 개발중인 의약품
• 골다공증 치료제 개발 파이프라인 개요

제6장 규제 구조

• 규제 개요
• 미국
• 의약품 개발과 승인 프로세스
• FDA가 심사하는 신청 종류
• 캐나다
• Food and Drugs Act(F-27)
• 유럽
• 일본

제7장 시장 세분화 분석

• 세분화 내역
• 시장 분석 : 여성 고유 질환별
• 유방암
• 폐경후 골다공증
• 폐경
• 자궁내막증
• PCOS
• 지역적 내역
• 시장 분석 : 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제8장 경쟁 구도

• 개요
• 진출 기업과 전략
• 특허 분석
• 주요 전개

제9장 ESG 관점

• ESG : 소개
• 제약 업계 ESG 목표
• 에너지 효율에 중점
• 배출량과 이산화탄소 배출량을 절감
• 폐기물 발생과 처분
• 제조, 유통, 운송
• 사회적 책임
• 거버넌스
• 제약 업계 ESG 리스크 평가
• BCC 조사에서 결론

제10장 부록

• 조사 방법
• 정보 출처
• 약어
• 기업 개요
• ABBVIE INC.
• AMGEN INC.
• ASAHI KASEI CORP.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

영문목차

The global therapeutics for women’s health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.

The North American therapeutics for women’s health technologies market is expected to grow from $28.4 billion in 2024 and is projected to reach $37.4 billion by the end of 2029, at a CAGR of 5.6% during the forecast period of 2024 to 2029.

The European therapeutics for women’s health technologies market is expected to grow from $17.7 billion in 2024 and is projected to reach $23.5 billion by the end of 2029, at a CAGR of 5.8% during the forecast period of 2024 to 2029.

Report Scope

This report provides a detailed analysis of the global therapeutics for women's health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market's competitive environment and products. The report presents market estimates and forecasts for women's health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women's health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market's leading players that feature detailed information about each company's business segments, financials, product portfolios and recent developments.

By region, the global therapeutics for women's health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report's market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.

Report Includes

• 46 data tables and 63 additional tables
• An overview of the global market and technologies for women's health therapeutics
• Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Study of women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors -and genetic factors, diagnosis, and treatment options
• Discussion on aging and women's health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer
• Information about significant products, companies, issues and trends affecting the women's disorders and diseases industry
• Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women's health therapeutics
• Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
• Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
• A discussion of ESG challenges and practices in the industry
• Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
• Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Insights

Chapter 2 Market Overview

• Overview
• Definitions
• Breast Cancer
• Postmenopausal Osteoporosis
• Menopause
• Endometriosis
• Polycystic Ovary Syndrome (PCOS)
• Historical Context
• Aging and Women's Health Disorders

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Population of Older Women
• Increasing Awareness and Accessibility
• Market Restraints
• High Treatment Costs
• Regulatory Challenges
• Market Opportunities
• Advances in Personalized Medicine
• Emerging Markets

Chapter 4 Emerging Technologies

• Overview
• Digital Health Solutions
• Advanced Fertility Technologies
• Targeted Biologics and Biosimilars
• Nanotechnology-Driven Drug Delivery
• Gene Therapy and CRISPR

Chapter 5 Pipeline Assessment and Analysis

• Overview
• Women's Health Therapeutics: Key Clinical Trial Developments
• Drugs in Pipeline
• Overview of Osteoporosis Drug Development Pipeline

Chapter 6 Regulatory Structure

• Overview of Regulations
• U.S.
• Drug Development and Approval Process
• Types of Applications Reviewed by FDA
• Canada
• Food and Drugs Act (F-27)
• Europe
• Japan

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Women's Health Disorder
• Breast Cancer
• Postmenopausal Osteoporosis
• Menopause
• Endometriosis
• PCOS
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Competitive Landscape

• Overview
• Market Players and Strategies
• Patent Analysis
• Key Developments

Chapter 9 ESG Perspective

• Introduction to ESG
• ESG Goals for the Pharmaceutical Sector
• Focus on Energy Efficiency
• Reduce Emissions and Carbon Footprint
• Waste Generation and Disposal
• Manufacturing, Distribution and Transportation
• Social Responsibility
• Governance
• ESG Risk Ratings in the Pharmaceutical Industry
• Concluding Remarks from BCC Research

Chapter 10 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASAHI KASEI CORP.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.